
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS ’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
This whitepaper presents a structured analysis of prior authorization outcomes for RA treatments requiring medical benefit coverage. It examines real-world access barriers from the perspective of payer decision patterns, documentation requirements, site of care, and plan type. Unlike claims-based studies or survey-based research, this analysis draws from actual prior authorization cases, providing a direct window into the real-world challenges faced by prescribers and patients alike.






